Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 2
1987 1
1989 2
1991 3
1992 3
1993 2
1994 3
1995 1
1996 3
1997 2
1998 3
1999 2
2000 3
2001 5
2002 7
2003 13
2004 17
2005 13
2006 14
2007 26
2008 23
2009 53
2010 53
2011 58
2012 86
2013 98
2014 114
2015 120
2016 159
2017 163
2018 198
2019 245
2020 274
2021 325
2022 349
2023 337
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

2,515 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).
Wang F, He MM, Xiao J, Zhang YQ, Yuan XL, Fang WJ, Zhang Y, Wang W, Hu XH, Ma ZG, Yao YC, Zhuang ZX, Zhou FX, Ying JE, Yuan Y, Zou QF, Guo ZQ, Wu XY, Jin Y, Mai ZJ, Wang ZQ, Qiu H, Guo Y, Shi SM, Chen SZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH. Wang F, et al. Among authors: zou qf. Clin Cancer Res. 2022 Oct 3;28(19):4232-4239. doi: 10.1158/1078-0432.CCR-22-0655. Clin Cancer Res. 2022. PMID: 35929990 Free PMC article. Clinical Trial.
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Among authors: zou q. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.
Editorial: Insights in computational genomics: 2022.
Emes RD, Pirooznia M, Zou Q, Pellegrini M. Emes RD, et al. Among authors: zou q. Front Genet. 2023 Jul 24;14:1256011. doi: 10.3389/fgene.2023.1256011. eCollection 2023. Front Genet. 2023. PMID: 37554406 Free PMC article. No abstract available.
Anti-phospholipid autoantibodies in human diseases.
Qin R, Wu H, Guan H, Tang C, Zheng Z, Deng C, Chen C, Zou Q, Lu L, Ma K. Qin R, et al. Among authors: zou q. Clin Immunol. 2023 Nov;256:109803. doi: 10.1016/j.clim.2023.109803. Epub 2023 Oct 19. Clin Immunol. 2023. PMID: 37821073 Review.
2,515 results